scholarly article | Q13442814 |
P50 | author | Michael R. Hayden | Q6833706 |
P2093 | author name string | Jun Wu | |
Ilya Bezprozvanny | |||
Iris Grossman | |||
Rebecca Kusko | |||
Michal Geva | |||
Daniel Ryskamp | |||
P2860 | cites work | The dopamine stabilizers ACR16 and (−)-OSU6162 display nanomolar affinities at the σ-1 receptor | Q60049913 |
The sigma-1 receptor enhances brain plasticity and functional recovery after experimental stroke | Q60597042 | ||
Sigma Receptor Type 1 Gene Variation in a Group of Polish Patients with Alzheimer’s Disease and Mild Cognitive Impairment | Q61945786 | ||
Dendritic and axonal targeting of type 5 metabotropic glutamate receptor is regulated by homer1 proteins and neuronal excitation | Q73258556 | ||
The sigma enigma: in vitro/in silico site-directed mutagenesis studies unveil σ1 receptor ligand binding | Q87753078 | ||
The Homer family proteins | Q21184127 | ||
Homer binds a novel proline-rich motif and links group 1 metabotropic glutamate receptors with IP3 receptors | Q22007971 | ||
Huntingtin and huntingtin-associated protein 1 influence neuronal calcium signaling mediated by inositol-(1,4,5) triphosphate receptor type 1 | Q24310249 | ||
A mutation in sigma-1 receptor causes juvenile amyotrophic lateral sclerosis | Q24322790 | ||
Neuroprotective effects of inositol 1,4,5-trisphosphate receptor C-terminal fragment in a Huntington's disease mouse model | Q24647950 | ||
Role of sigma-1 receptor C-terminal segment in inositol 1,4,5-trisphosphate receptor activation: constitutive enhancement of calcium signaling in MCF-7 tumor cells | Q24652395 | ||
The synaptic maintenance problem: membrane recycling, Ca2+ homeostasis and late onset degeneration | Q27000356 | ||
Crystal structure of the human σ1 receptor | Q27704518 | ||
Role of sigma-1 receptors in neurodegenerative diseases | Q28082554 | ||
Homer 1b regulates the trafficking of group I metabotropic glutamate receptors | Q28143150 | ||
Generation and phenotypic analysis of sigma receptor type I (σ1) knockout mice | Q28184848 | ||
Agonist-independent activation of metabotropic glutamate receptors by the intracellular protein Homer | Q28202988 | ||
Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca(2+) signaling and cell survival | Q28255981 | ||
A SIGMAR1 splice-site mutation causes distal hereditary motor neuropathy | Q28263528 | ||
The scaffold protein Homer1b/c links metabotropic glutamate receptor 5 to extracellular signal-regulated protein kinase cascades in neurons | Q28583632 | ||
The sigma-1 receptor is enriched in postsynaptic sites of C-terminals in mouse motoneurons. An anatomical and behavioral study | Q28592425 | ||
Automated three-dimensional detection and shape classification of dendritic spines from fluorescence microscopy images | Q28755127 | ||
limma powers differential expression analyses for RNA-sequencing and microarray studies | Q29617988 | ||
CRISPR-Cas9 knockin mice for genome editing and cancer modeling | Q30607892 | ||
Reduced synaptic STIM2 expression and impaired store-operated calcium entry cause destabilization of mature spines in mutant presenilin mice | Q33554241 | ||
Postsynaptic scaffold protein Homer 1a protects against traumatic brain injury via regulating group I metabotropic glutamate receptors | Q33654169 | ||
Expression of inositol trisphosphate receptors. | Q33834374 | ||
Disturbed Ca2+ signaling and apoptosis of medium spiny neurons in Huntington's disease. | Q33850154 | ||
Cognition and depression: the effects of fluvoxamine, a sigma-1 receptor agonist, reconsidered | Q34108906 | ||
Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial | Q34231219 | ||
The dopaminergic stabiliser ACR16 counteracts the behavioural primitivization induced by the NMDA receptor antagonist MK-801 in mice: implications for cognition | Q34336118 | ||
The sigma-1 receptor chaperone as an inter-organelle signaling modulator | Q34356970 | ||
Abnormal motor cortex plasticity in premanifest and very early manifest Huntington disease | Q34382326 | ||
Abnormal motor cortex excitability in preclinical and very early Huntington's disease | Q34386162 | ||
Effects of (-)-OSU6162 and ACR16 on motor activity in rats, indicating a unique mechanism of dopaminergic stabilization | Q34763003 | ||
Dendritic spine instability leads to progressive neocortical spine loss in a mouse model of Huntington's disease. | Q34910148 | ||
The dopaminergic stabilizers pridopidine (ACR16) and (-)-OSU6162 display dopamine D(2) receptor antagonism and fast receptor dissociation properties | Q35013323 | ||
Neuronal store-operated calcium entry pathway as a novel therapeutic target for Huntington's disease treatment | Q35072356 | ||
Inhibition of store-operated calcium entry attenuates MPP(+)-induced oxidative stress via preservation of mitochondrial function in PC12 cells: involvement of Homer1a | Q35073154 | ||
Pharmacological stimulation of sigma-1 receptors has neurorestorative effects in experimental parkinsonism | Q35154720 | ||
Improved vectors and genome-wide libraries for CRISPR screening | Q35215629 | ||
Late-onset inner retinal dysfunction in mice lacking sigma receptor 1 (σR1). | Q35247759 | ||
Differences in duration of Huntington's disease based on age at onset | Q35449269 | ||
Sigma-1 receptor regulates Tau phosphorylation and axon extension by shaping p35 turnover via myristic acid | Q35669383 | ||
The sigma-1 receptor protects against cellular oxidative stress and activates antioxidant response elements | Q35856904 | ||
A perspective on the new mechanism of antidepressants: neuritogenesis through sigma-1 receptors | Q35952491 | ||
STIM2 protects hippocampal mushroom spines from amyloid synaptotoxicity | Q35954470 | ||
Sigma 1 receptor regulates the oxidative stress response in primary retinal Müller glial cells via NRF2 signaling and system xc(-), the Na(+)-independent glutamate-cystine exchanger | Q36011646 | ||
Scaffolding protein Homer1a protects against NMDA-induced neuronal injury | Q36022288 | ||
Neuronal Store-Operated Calcium Entry and Mushroom Spine Loss in Amyloid Precursor Protein Knock-In Mouse Model of Alzheimer's Disease. | Q36106832 | ||
Enhanced Store-Operated Calcium Entry Leads to Striatal Synaptic Loss in a Huntington's Disease Mouse Model. | Q36431970 | ||
Neuro(active)steroids actions at the neuromodulatory sigma1 (sigma1) receptor: biochemical and physiological evidences, consequences in neuroprotection | Q36582899 | ||
The sigma-1 receptor: roles in neuronal plasticity and disease | Q36653400 | ||
Involvement of unique leucine-zipper motif of PSD-Zip45 (Homer 1c/vesl-1L) in group 1 metabotropic glutamate receptor clustering | Q36702025 | ||
Preface | Q36717105 | ||
Sigma1 receptors inhibit store-operated Ca2+ entry by attenuating coupling of STIM1 to Orai1 | Q36789920 | ||
Homer proteins in Ca2+ signaling by excitable and non-excitable cells | Q36873568 | ||
In vivo protection against retinal neurodegeneration by sigma receptor 1 ligand (+)-pentazocine | Q36925899 | ||
A prototypical Sigma-1 receptor antagonist protects against brain ischemia | Q36976939 | ||
Insights into the Sigma-1 receptor chaperone's cellular functions: a microarray report | Q36995785 | ||
The pharmacology of sigma-1 receptors | Q37445561 | ||
Sigma-1 receptors regulate hippocampal dendritic spine formation via a free radical-sensitive mechanism involving Rac1xGTP pathway | Q37471826 | ||
Early synaptic pathophysiology in neurodegeneration: insights from Huntington's disease | Q37789909 | ||
Homer proteins in Ca²⁺ entry. | Q38095898 | ||
Corticostriatal circuit dysfunction in Huntington's disease: intersection of glutamate, dopamine and calcium | Q38603960 | ||
Pridopidine, a dopamine stabilizer, improves motor performance and shows neuroprotective effects in Huntington disease R6/2 mouse model | Q38861728 | ||
Sigma-1 receptor agonist PRE084 is protective against mutant huntingtin-induced cell degeneration: involvement of calpastatin and the NF-κB pathway. | Q39148056 | ||
Sigma nonopioid intracellular receptor 1 mutations cause frontotemporal lobar degeneration-motor neuron disease. | Q39638549 | ||
Pridopidine selectively occupies sigma-1 rather than dopamine D2 receptors at behaviorally active doses | Q40753593 | ||
Co-expression of metabotropic glutamate receptor type 1alpha with homer-1a/Vesl-1S increases the cell surface expression of the receptor | Q40940136 | ||
The anti-amnesic and neuroprotective effects of donepezil against amyloid beta25-35 peptide-induced toxicity in mice involve an interaction with the sigma1 receptor | Q41603023 | ||
Pridopidine activates neuroprotective pathways impaired in Huntington Disease | Q42324179 | ||
Anti-amnesic and neuroprotective actions of the sigma-1 receptor agonist (-)-MR22 in rats with selective cholinergic lesion and amyloid infusion. | Q42483575 | ||
Genetic analysis of SIGMAR1 as a cause of familial ALS with dementia | Q42791389 | ||
Efficacy and safety of the dopaminergic stabilizer Pridopidine (ACR16) in patients with Huntington's disease | Q42975568 | ||
Cocaine inhibits store-operated Ca2+ entry in brain microvascular endothelial cells: critical role for sigma-1 receptors | Q43129017 | ||
Solution NMR studies reveal the location of the second transmembrane domain of the human sigma-1 receptor. | Q43152603 | ||
Low density of sigma1 receptors in early Alzheimer's disease | Q44014199 | ||
SKF-96365 attenuates toxin-induced neuronal injury through opposite regulatory effects on Homer1a and Homer1b/c in cultured rat mesencephalic cells | Q44296254 | ||
σ-1 Receptors (σ1Binding Sites) Form Raft-Like Microdomains and Target Lipid Droplets on the Endoplasmic Reticulum: Roles in Endoplasmic Reticulum Lipid Compartmentalization and Export | Q44429451 | ||
Antiamnesic and neuroprotective effects of the aminotetrahydrofuran derivative ANAVEX1-41 against amyloid beta(25-35)-induced toxicity in mice | Q44617703 | ||
Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease | Q45289366 | ||
Huntington disease: Clinical care and evaluation | Q45290085 | ||
A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington's disease | Q45292205 | ||
Calbindin D28K as a marker for the degeneration of the striatonigral pathway in Huntington's disease | Q45294692 | ||
Clinical and neuropathologic assessment of severity in Huntington's disease | Q45298780 | ||
Regional cerebral glucose metabolism after pridopidine (ACR16) treatment in patients with Huntington disease | Q45302933 | ||
Corticostriatal synaptic function in mouse models of Huntington's disease: early effects of huntingtin repeat length and protein load | Q45306738 | ||
Anti-amnesic properties of (+/-)-PPCC, a novel sigma receptor ligand, on cognitive dysfunction induced by selective cholinergic lesion in rats. | Q46107849 | ||
Calbindin d28k overexpression protects striatal neurons from transient focal cerebral ischemia | Q46132048 | ||
Neuroprotective effects of sigma-1 receptor agonists against beta-amyloid-induced toxicity. | Q46596943 | ||
Association between a variant of the sigma-1 receptor gene and Alzheimer's disease | Q47803612 | ||
High Ca2+-phosphate transfection efficiency in low-density neuronal cultures | Q48218879 | ||
Dysfunction in endoplasmic reticulum-mitochondria crosstalk underlies SIGMAR1 loss of function mediated motor neuron degeneration. | Q48330721 | ||
Huntington disease | Q48465200 | ||
Relative sparing in Parkinson's disease of substantia nigra dopamine neurons containing calbindin-D28K. | Q48899006 | ||
The presence of calbindin in rat cortical neurons protects in vitro from oxydative stress | Q49160218 | ||
A variant of the sigma receptor type-1 gene is a protective factor for Alzheimer disease. | Q51986787 | ||
Investigation of the role of sigma1-receptors in inositol 1,4,5-trisphosphate dependent calcium signaling in hepatocytes. | Q54585068 | ||
Huntington disease | Q56083219 | ||
P4510 | describes a project that uses | limma | Q112236343 |
ImageJ | Q1659584 | ||
P433 | issue | Pt A | |
P921 | main subject | Huntington's disease | Q190564 |
P304 | page(s) | 46-59 | |
P577 | publication date | 2016-11-03 | |
P1433 | published in | Neurobiology of Disease | Q15716606 |
P1476 | title | The sigma-1 receptor mediates the beneficial effects of pridopidine in a mouse model of Huntington disease | |
P478 | volume | 97 |
Q55438236 | Altering cortical input unmasks synaptic phenotypes in the YAC128 cortico-striatal co-culture model of Huntington disease. |
Q89963647 | Axonal Endoplasmic Reticulum Dynamics and Its Roles in Neurodegeneration |
Q50088379 | Cause or compensation?-Altered neuronal Ca2+ handling in Huntington's disease. |
Q64077579 | Combinatorial treatment increases IKAP levels in human cells generated from Familial Dysautonomia patients |
Q57073756 | Drug Screening Identifies Sigma-1-Receptor as a Target for the Therapy of VWM Leukodystrophy |
Q45305901 | Early pridopidine treatment improves behavioral and transcriptional deficits in YAC128 Huntington disease mice. |
Q92478041 | Impairment and Restoration of Homeostatic Plasticity in Cultured Cortical Neurons From a Mouse Model of Huntington Disease |
Q52430483 | Inhibition of TRPC1-Dependent Store-Operated Calcium Entry Improves Synaptic Stability and Motor Performance in a Mouse Model of Huntington's Disease. |
Q55335504 | Large-scale transcriptomic analysis reveals that pridopidine reverses aberrant gene expression and activates neuroprotective pathways in the YAC128 HD mouse. |
Q90679929 | Mutational Analysis of Sigma-1 Receptor's Role in Synaptic Stability |
Q90263450 | Neuronal Sigma-1 Receptors: Signaling Functions and Protective Roles in Neurodegenerative Diseases |
Q47410169 | Neuroprotective Effect of σ1-Receptors on the Cell Model of Huntington's Disease |
Q52721231 | On the Role of Store-Operated Calcium Entry in Acute and Chronic Neurodegenerative Diseases. |
Q92328222 | Partners in Crime: Towards New Ways of Targeting Calcium Channels |
Q52564664 | Pridopidine Reverses Phencyclidine-Induced Memory Impairment. |
Q92158893 | Pridopidine protects neurons from mutant-huntingtin toxicity via the sigma-1 receptor |
Q52685691 | Pridopidine: Overview of Pharmacology and Rationale for its Use in Huntington's Disease. |
Q64079932 | Protein Misfolding and ER Stress in Huntington's Disease |
Q41716404 | Role of the sigma-1 receptor chaperone in rod and cone photoreceptor degenerations in a mouse model of retinitis pigmentosa |
Q41714466 | Roles of sigma-1 receptors on mitochondrial functions relevant to neurodegenerative diseases |
Q67228612 | Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study |
Q101226279 | Sigma-1 receptor chaperones rescue nucleocytoplasmic transport deficit seen in cellular and Drosophila ALS/FTD models |
Q64075421 | Targeting the Sigma-1 Receptor via Pridopidine Ameliorates Central Features of ALS Pathology in a SOD1 Model |
Q50973291 | The Role of Sigma-1 Receptor, an Intracellular Chaperone in Neurodegenerative Diseases. |
Q64859904 | Therapeutic approaches to Huntington disease: from the bench to the clinic |
Q47977953 | Treatment options for chorea |
Search more.